Glasgow, UK – 13th March 2019 – Lamellar Biomedical Limited (Lamellar), an innovative biotechnology company, pioneering new approaches for the safe and effective transfer of functional nucleic acids, announces two research partnerships to further optimise its LAMELLASOME™ Nucleic Acid technology platform and its product manufacturing processes. The partnerships are with the University of Strathclyde and Edinburgh University. Lamellar believes its LAMELLASOME NAT (Nucleic Acid Transfer) technology will play a key role in realising the potential of many of the nucleic acids in development, including siRNAs, microRNAs, mRNAs and plasmids, potentially revolutionising the treatment of numerous rare and intractable diseases.
Alec McLean, CEO of Lamellar Biomedical, said: “We are very pleased to announce these partnerships with two world-class research institutions. Together these research collaborations will contribute to further advancing our lead products for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and Cystic Fibrosis (CF). It will support our external collaborations with pharma in developing LAMELLASOME™ formulations for the safe and effective delivery of their novel nucleic acids across a spectrum of therapeutic areas.”
The first partnership, with Professor Yvonne Perrie (Chair in Drug Delivery) of the University of Strathclyde’s Institute of Pharmacy and Biomedical Sciences, is building upon pioneering work that will enable Lamellar to develop LAMELLASOME™ formulations optimised for the delivery of specific active substances.
The second partnership, with Edinburgh University’s Complex Fluid Partnership, allows Lamellar to test and optimise the biophysical properties of LAMELLASOME™ formulations regarding the ability to alter biological gels including CF sputum and bacterial biofilms to facilitate the delivery of pulmonary nucleic acids. This knowledge will also help us advance the development of other novel products for a range of therapeutic areas. Both projects are funded through the UK KTP program in conjunction with Lamellar for a duration of two years.
Margaret Courtney (Director for Manufacture at Lamellar) noted that “Lamellar are very excited about the award of these two partnerships that are designed to expand applications of the LAMELLASOME platform and further advance our manufacturing processes, with a focus on the reduction in formulation complexity, costs and time to market”
|For further information, please contact:|
|Dr Alec McLean||+44 (0) 1698 748 832 +44 (0) 1698 532 163|
|Citigate Dewe Rogerson|
|David Dible/ Pip Batty/Shabnam Bashiremail@example.com|
About Lamellar Biomedical
Lamellar Biomedical Limited (Lamellar), is an innovative biotechnology company, pioneering new approaches for the transfer of functional nucleic acids. The Company’s unique and versatile LAMELLASOME™ platform has been designed for the safe and effective delivery of nucleic acid-based therapeutics. Lamellar believes that its LAMELLASOME™ technology will play a key role in realising the potential of mRNAs, siRNAs, miRs, plasmids and other nucleic acids in development offering the potential to revolutionise the treatment of many rare and intractable diseases.
LAMELLASOME formulations have been shown to be effective in delivering functional nucleic acids to a range of cell types including macrophages, human pulmonary fibroblasts and human dendritic cells. The technology has also been successfully used for the in vivo delivery of functional nucleic acids.
Lamellar is developing its own pipeline of nucleic acid-based therapeutics, the most advanced of which target two areas of unmet clinical need: Idiopathic Pulmonary Fibrosis and Cystic Fibrosis.
Founded in 2007, Lamellar is backed by both institutional and private investors, including Invesco, Scottish Enterprise, Barwell Plc, TRI Capital and has multiple research collaborations with world renowned institutions and universities.
LAMELLASOME™ technology comprises synthetic lipid vesicles with compositions based on human lamellar bodies/exosomes. LAMELLASOME technology represents a considerable advance in safe and effective non-viral transfection and is distinct from cationic and divalent-ion liposomal systems. LAMELLASOME monotherapy formulations have excellent preclinical safety, a very high NOAEL (taken from inhalation toxicology) and excellent clinical safety and tolerability profile.
Lamellar Biomedical can construct novel and bespoke LAMELLASOME formulations and thus optimise the delivery of specific active-agent nucleic acids. Lamellar Biomedical intends to tailor its LAMELLASOME technology to safely and effectively deliver nucleic acid-based therapeutics to their target cells in order to optimise their functionality.